Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945915 | 0.82 | HDAC1 (0.73) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL7945896 | 0.80 | HDAC1 (0.57) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL5020692 | 0.76 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL1232897 | 0.74 | HDAC1 (0.74) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL1232899 | 0.74 | HDAC1 (0.74) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL9987472 | 0.71 | HDAC1 (0.74) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL7935110 | 0.71 | HDAC1 (0.74) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL3814616 | 0.71 | HDAC1 (0.62) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL674308 | 0.71 | HDAC1 (0.62) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL10827609 | 0.71 | CYP2C9 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157174-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2017-06-08 | — | — | US | disclosed |
| US-20170157174-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2017-06-08 | — | — | US | disclosed |
| EP-2349245-B1 | TREATMENT OF LATENT HIV-1 INFECTIONS USING AURANOFIN OR ARSENIC TRIOXIDE | Istituto Superiore di Sanità (IT) | 2016-08-03 | — | — | EP | disclosed |
| US-20150024065-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2015-01-22 | — | — | US | disclosed |
| US-20150024065-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2015-01-22 | — | — | US | disclosed |
| US-8785493-B2 | Treatment of retroviral reservoirs exploiting oxidative stress | ISTITUTO SUPERIORE DI SANITA (IT) | 2014-07-22 | — | — | US | disclosed |
| US-8785493-B2 | Treatment of retroviral reservoirs exploiting oxidative stress | ISTITUTO SUPERIORE DI SANITA (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20110305774-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2011-12-15 | — | — | US | disclosed |
| WO-2010049182-A2 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITÁ (IT) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305774-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | TXNRD1, TXNRD3, TXNRD2 | HDAC1 506/4885HDAC8 1893/4885HDAC6 1260/4885 |
| US-20170157174-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | TXNRD1, TXNRD3, TXNRD2 | HDAC1 506/4885HDAC8 1893/4885HDAC6 1260/4885 |
| US-20150024065-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | TXNRD1, TXNRD3, TXNRD2 | HDAC1 506/4885HDAC8 1893/4885HDAC6 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.